PeptidePedia The community reference

Dipeptidyl peptidase-4: difference between revisions

Diff·revision 16 → 17·06:05, 28 Mar 2025

Difference between revision 16 and revision 17 of Dipeptidyl peptidase-4. 3 lines changed; the page grew by 259 bytes.

Revision 16 — 05:39, 2 Mar 2025
CategoryBot (talk)
bot: sort category members
5,763 bytes ±0
Revision 17 — 06:05, 28 Mar 2025
LCellLeif (talk)
state that the receptor is a class B G-protein-coupled receptor
6,022 bytes +259
46The clinical consequences follow from that ceiling. Glycated-haemoglobin reduction is modest, weight is unchanged rather than reduced, and gastrointestinal adverse effects are uncommon — the same mechanism that limits efficacy also limits toxicity. Cardiovascular outcome trials of the class have been neutral for major adverse cardiovascular events, with a signal for heart-failure hospitalisation reported for one member.{{r|deacon2019}}46The clinical consequences follow from that ceiling. Glycated-haemoglobin reduction is modest, weight is unchanged rather than reduced, and gastrointestinal adverse effects are uncommon — the same mechanism that limits efficacy also limits toxicity. Cardiovascular outcome trials of the class have been neutral for major adverse cardiovascular events, with a signal for heart-failure hospitalisation reported for one member.{{r|deacon2019}}
4747
+48Because the inhibitors act on endogenous hormone, they are not interchangeable with receptor agonists and combining the two produces little additional benefit — receptor occupancy is already near-maximal under agonist therapy.
+49
48== References ==50== References ==
49{{reflist}}51{{reflist}}
57* [[GLP-1 receptor agonist]]59* [[GLP-1 receptor agonist]]
58* [[Albumin binding half-life extension]]60* [[Albumin binding half-life extension]]
+61* [[Enteroendocrine L cell]]
5962
60{{DEFAULTSORT:Dipeptidyl peptidase-4}}63{{DEFAULTSORT:Dipeptidyl peptidase-4}}